<DOC>
	<DOC>NCT01396083</DOC>
	<brief_summary>This clinical trial is designed to compare ranibizumab in comparison with Dexamethasone implant® after 6 months of treatment. In the study arm Lucentis will be given monthly in a pro re nata scheme whereas the comparator Dexamethasone implant is given once at Month 0 with sham injections PRN afterwards.</brief_summary>
	<brief_title>Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients diagnosed with visual impairment due to macular edema following CRVO Diagnosis of CRVO at maximum 6 months prior to Screening BCVA using ETDRS charts of 20/40 to 20/400 in the study eye Media clarity, pupillary dilation and patient cooperation not sufficient for adequate fundus photographs Central retinal thickness (CRT) &lt; 250 µm in the study eye Prior episode of RVO in the study eye Active formation of new vessels in the study eye AntiVEGFtreatment in the study or the fellow eye 3 months prior to Baseline IOP ≥ 30mmHg or uncontrolled glaucoma; patients may be rescreened after 1 month if they have undergone glaucoma treatment Improvement of &gt; 10 letters on BCVA between Screening and Baseline Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Visual impairment</keyword>
	<keyword>macular edema</keyword>
	<keyword>Central retinal vein occlusion</keyword>
	<keyword>Dexamethasone implant</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>